
Opinion|Videos|August 20, 2024
Comparing Cretostimogene and BCG Administration Methods
Experts compare Cretostimogene and BCG Administration Methods
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Can you describe the therapy dose, mode of administration, and duration?
- How does the administration method of cretostimogene compare to that of BCG?
- What were the primary and secondary endpoints of this trial?
Advertisement
Related to this article

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
3
Treatment Targets, Formulations, and the Future of Testosterone
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5



